Stephens Investment Management Group LLC Decreases Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Stephens Investment Management Group LLC lessened its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 0.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,346,957 shares of the biopharmaceutical company's stock after selling 12,773 shares during the quarter. Stephens Investment Management Group LLC owned about 1.06% of Halozyme Therapeutics worth $64,398,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Heck Capital Advisors LLC acquired a new position in Halozyme Therapeutics in the fourth quarter worth about $29,000. GAMMA Investing LLC grew its holdings in Halozyme Therapeutics by 67.7% in the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company's stock worth $50,000 after buying an additional 350 shares in the last quarter. Toth Financial Advisory Corp acquired a new stake in Halozyme Therapeutics in the third quarter worth approximately $57,000. FSC Wealth Advisors LLC acquired a new stake in Halozyme Therapeutics in the third quarter worth approximately $65,000. Finally, CWM LLC lifted its position in Halozyme Therapeutics by 77.5% in the third quarter. CWM LLC now owns 1,530 shares of the biopharmaceutical company's stock worth $88,000 after purchasing an additional 668 shares during the period. Institutional investors and hedge funds own 97.79% of the company's stock.

Analyst Ratings Changes

HALO has been the subject of several recent analyst reports. JMP Securities raised their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a "market outperform" rating in a research report on Friday, November 1st. Piper Sandler raised their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a report on Friday, January 10th. Cowen restated a "buy" rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Wells Fargo & Company dropped their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research note on Monday, January 13th. Finally, HC Wainwright reiterated a "buy" rating and issued a $70.00 price objective on shares of Halozyme Therapeutics in a research note on Tuesday, February 4th. Four equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, Halozyme Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $60.89.

Halozyme Therapeutics Price Performance

HALO stock traded up $0.78 during mid-day trading on Wednesday, hitting $58.11. The stock had a trading volume of 888,165 shares, compared to its average volume of 1,286,692. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics, Inc. has a 52 week low of $34.36 and a 52 week high of $65.53. The firm has a market capitalization of $7.39 billion, a P/E ratio of 19.24, a P/E/G ratio of 0.44 and a beta of 1.25. The firm has a fifty day simple moving average of $52.09 and a 200 day simple moving average of $54.45.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of the company's stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total transaction of $281,500.00. Following the transaction, the director now owns 38,611 shares in the company, valued at approximately $2,173,799.30. This represents a 11.46 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 2.40% of the company's stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.